Pharmaceuticals
Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults
– In a dual-review process, two independent advisory committees to the Australian Minister for Health recommended reimbursement based on a favorable clinical and cost-effectiveness comparison – DUBLIN and LAKEWOOD, Colo., Oct. 28, 2021 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global ...
2021-10-28 05:48
2758
Frontier Biotechnologies' Long-acting Injectable (Aikening(R)), in a Two Drug Regimen, Proves Safe and Effective for Critically Ill Hospitalized AIDS Patients
LONDON, Oct. 27, 2021 /PRNewswire/ -- Frontier Biotechnologies today shared real-world evidence of Albuvirtide (ABT)-based two drug regimen's safety and efficacy for hospitalized AIDS patients at the European AIDS Clinical Society (EACS) Conference. Observations from a single-center, retrospec...
2021-10-27 20:47
1461
Qilian International Holding Group Limited Completes Phase One of Its Expansion of New Organic Fertilizer Production Facility and Puts It into Production
JIUQUAN, China, Oct. 26, 2021 /PRNewswire/ -- Qilian International Holding Group Limited (Nasdaq: QLI) (the "Company"), aChina-based pharmaceutical and chemical products manufacturer, today announced that the Company has completed phase one of the expansion of its new organic fertilizer produc...
2021-10-26 20:00
2316
I-Mab Announces Strategic Partnership with Sinopharm in Preparation for Launch of its Innovative Assets in China
* I-Mab strategic partnership with Sinopharm will covers all aspects of the go-to-market process, including authorization of more than 300 Sinopharm's subsidiaries as distributors acrossChina. * I-Mab is on track to submit BLA for third line multiple myeloma (MM) treatment by Q4 2021. * The...
2021-10-26 20:00
3283
Samsung Biologics Reports Third Quarter 2021 Financial Results
* Q3'21 revenue of KRW 450.7 billion increased 64% compared to Q3'20. * Q3'21 operating profit of KRW 167.4 billion increased 196% compared to Q3'20. * Stable supply, strong operational excellence and a high utilization rate across all plants. * Active investment on expansion, pre-sales ac...
2021-10-26 15:23
2460
Angel Pharmaceuticals Announces Approval of IND Application in China for ITK Inhibitor CPI-818
JIAXING, China and BURLINGAME, Calif., Oct. 25, 2021 /PRNewswire/ -- Angel Pharmaceuticals Co., Ltd. ("Angel Pharma") today announced that its IND application for CPI-818, a small molecule ITK inhibitor, has been approved by the Center for Drug Evaluation (CDE) to initiate clinical trials in pati...
2021-10-26 07:30
2227
SCN9A Antisense Pain Killer OLP-1002 Moves into Phase 2a Stage
SEOUL, South Korea, Oct. 25, 2021 /PRNewswire/ -- OliPass Corporation, a South Korea based biotech specialized in the development of RNA therapeutics, announced to initiate a Phase 2a trial for SCN9A antisense pain killer OLP-1002 inAustralia. In the Phase 2a trial of a two stage adaptive design ...
2021-10-25 20:30
2333
111, Inc. Announces Strategic Partnership with Chugai Pharma China Co., Ltd. to Accelerate Innovations in Chronic Disease Management
SHANGHAI, Oct. 25, 2021 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, today announced a strategic cooperation agreement with Chugai Phar...
2021-10-25 19:00
2641
I-Mab Expands U.S. Footprint with New R&D Site in San Diego
- I-Mab will strengthen its global R&D presence, with a new world-class R&D and operational site, located in the heart of the rapidly growingSan Diego biotech hub - The new site will complement I-Mab's Global Clinical Development site in Gaithersburg, Maryland to form an integrated I-Mab US R&...
2021-10-22 20:00
2364
2021 Bio-enzyme Application Explorer Summit held in Chengdu
The event focuses on innovation and development of biochemical pharmaceuticals CHENGDU, China, Oct. 22, 2021 /PRNewswire/ -- The biochemical pharmaceutical industry is facing unprecedented opportunities and challenges with the changing economic and policy environment inChina and abroad. On Octobe...
2021-10-22 14:23
1909
Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore
SINGAPORE, Oct. 21, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner withIncyte Biosciences International Sàrl,the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and onc...
2021-10-22 09:00
2306
Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China
SUZHOU, China, Oct. 21 , 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) fo...
2021-10-21 22:33
2950
Luoxin Pharmaceutical signs licensing agreement with Austria-based Marinomed Biotech AG for Budesolv® Budesonide Nasal Spray
SHANGHAI, Oct. 21, 2021 /PRNewswire/ -- Shandong Luoxin Pharmaceutical Group Stock Co., Ltd. (''Shandong Luoxin''), a subsidiary of Luoxin Pharmaceutical Group Stock Co., Ltd. ("Luoxin Pharmaceutical" or "the company") , signed a licensing agreement withAustria-based Marinomed Biotech AG ("Mar...
2021-10-21 15:58
1979
GenFleet Announces First Patient Dosed in Phase Ib/II Trial of TGF-β R1 Inhibitor in Combination with PD-1 Inhibitor in Global Multi-center Research
PERTH, Australia and TAIPEI and SHANGHAI, Oct. 20, 2021 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the first patient with metastatic sigmoid adenocarcinoma has been dosed inPerth, Aus...
2021-10-21 08:05
2413
Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference
* Statistically significant 133% faster time to COVID-19 clinical symptoms recovery versus standard of care (SOC)/best supportive care. * Statistically significant 114% faster time to reach EQ-5D-5L Q6 ≥ 90% versus SOC/best supportive care. * Statistically significant 57% faster time to norm...
2021-10-20 20:52
2687
Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
- Clinical trial to enroll patients with early-stage Multiple Systems Atrophy (MSA) - - Expanding bioMUSE Natural History Study - MELBOURNE, Australia and SAN FRANCISCO, Oct. 19, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology c...
2021-10-20 05:08
2580
InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China
BEIJING, Oct. 19, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval from the NMPA for itsSHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189, which is the company's...
2021-10-19 12:56
2427
The Journal of Medicinal Chemistry Publishes Study Showing Potential of the Potent EED Inhibitor EEDi-5273 (APG-5918) to Achieve Complete Tumor Regression by Modulating the Epigenetics
SUZHOU, China, and ROCKVILLE, Md., Oct. 18, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a research team led by Prof. Shaomeng Wang, ...
2021-10-18 22:42
8648
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China ...
2021-10-18 20:00
2211
Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
HONG KONG, Oct. 15, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Company's self-developed innovative drug candidate, IL-4R monoclonal antibody (AK120), was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration ofthe People...
2021-10-15 12:44
2524
Week's Top Stories
Most Reposted
Visa Expands Support for its Clients and the Industry as Organisations Navigate New AI Era of Cybersecurity
[Picked up by 320 media titles]
2026-08-28 09:01Agoda Named Official Travel Partner of Eurovision's Inaugural Asian Edition
[Picked up by 312 media titles]
2026-09-02 12:17
Visa Launches Enhanced A2A Protect Innovations to Help Financial Institutions Stop Fraud Before Money Leaves Accounts
[Picked up by 310 media titles]
2026-09-02 08:30Klook Takes Creator Commerce Beyond Influence With Kreator Shops
[Picked up by 307 media titles]
2026-09-01 11:00
DayOne and TNB Explore Up To 1.5 GW of On-Site Power Generation to Advance Malaysia's Energy Resilience and Digital Economy
[Picked up by 292 media titles]
2026-09-01 17:36